https://www.selleckchem.com/pr....oducts/act001-dmamcl
However, none of the agents that block the CD40/CD154 pathway are yet approved for clinical use, and so this hurdle remains to be overcome. The role of anti-inflammatory agents remains unproven. The major difference between this suggested regimen and those used in allotransplantation is the replacement of a calcineurin inhibitor with a costimulation blockade agent, but this does not appear to increase the complications of the regimen. Kidney transplantation is the best alternative treatment for end-stage renal disease (ESRD). In o
Like
Comment
Share
